Oneness Biotech announced that its Bonvadis (Fespixon) topical cream has been granted a medical device marketing authorization by Colombia’s INVIMA for the "Complete Wound" indication.

• Indication Scope: The authorization covers acute wounds (lacerations, abrasions, burns), chronic wounds (diabetic foot ulcers, pressure sores, venous ulcers, post-surgical wounds), and scar reduction by maintaining a moist wound environment.
• Strategic Entry: This marks the first "Complete Wound" indication approval for Bonvadis in Latin America. According to the International Diabetes Federation (IDF), Colombia has approximately 3 million diabetic patients (8.4% prevalence), a figure expected to rise to 4.3 million by 2050.
• Market Growth: The advanced wound care market in Colombia is projected to reach US$92.4 million by 2030, growing at a CAGR of 5.9%.

Resource: 合一Bonvadis外用乳膏 獲哥倫比亞核准完全傷口適應症醫材上市許可